The partners will seek CAP/CLIA certification for an organoid-based assay and conduct clinical validation studies of it as a tool to guide treatment.

NEW YORK – ARTBio this week said it has raised $132 million in Series B financing to advance its alpha radioligand therapies and bolster the supply chain underlying their development.

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

The agency previously declined to approve Atara's first Ebvallo biologics license application, but has accepted a data package it resubmitted this month.

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.

The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.

The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...